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Abstract
Background: Glioblastoma multiforme (GBM, WHO grade IV) is the most common and most malignant of astrocytic brain
tumors, and is associated with rapid invasion into neighboring tissue. In other tumor types it is well established that such
invasion involves a complex interaction between tumor cells and locally produced extracellular matrix. In GBMs, surprisingly
little is known about the associated matrix components, in particular the fibrillar proteins such as collagens that are known
to play a key role in the invasion of other tumor types.
Methodology/Principal Findings: In this study we have used both the Masson’s trichrome staining and a high resolution
multiple immunofluorescence labeling method to demonstrate that intratumoral fibrillar collagens are an integral part of
the extracellular matrix in a subset of GBMs. Correlated with this collagen deposition we observed high level expression of
the collagen-binding receptor Endo180 (CD280) in the tumor cells. Further, interrogation of multiple expression array
datasets identified Endo180 as one of the most highly upregulated transcripts in grade IV GBMs compared to grade III
gliomas. Using promoter analysis studies we show that this increased expression is, in part, mediated via TGF-b signaling.
Functionally, we demonstrate that Endo180 serves as the major collagen internalization receptor in GBM cell lines and
provide the first evidence that this activity is critical for the invasion of GBM cells through fibrillar collagen matrices.
Conclusions/Significance: This study demonstrates, for the first time, that fibrillar collagens are extensively deposited in
GBMs and that the collagen internalization receptor Endo180 is both highly expressed in these tumors and that it serves to
mediate the invasion of tumor cells through collagen-containing matrices. Together these data provide important insights
into the mechanism of GBM invasion and identify Endo180 as a potential target to limit matrix turnover by glioma cells and
thereby restrict tumor progression.
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Introduction
High-grade gliomas are the most common brain tumors in
adults, and are characterized by their treatment-refractory nature
and poor clinical outcome. They are classified into four grades as
defined by the World Health Organization [1]. Of these, grade IV
glioblastoma multiforme (GBM) tumors have the worst prognosis,
with median survival of 10–12 months. GBMs are characterized
by extensive microvascular proliferations and/or necrosis in
addition to the nuclear atypia and mitotic activity seen in grade
II and III tumors [1]. Moreover, complete surgical resection of
GBM is difficult due to the infiltration of tumor cells into the
surrounding brain tissue [2]. This invasive process is characterized
by adhesion of the tumor cells to locally produced extracellular
matrix (ECM) components, cell locomotion and the ability of
invading cells to remodel their local extracellular space [3,4].
The normal brain ECM has a unique composition consisting
mainly of hyaluronan, proteoglycans and tenascin-C and, apart
from the basement membrane of the normal brain vasculature, is
devoid of rigid protein barriers formed by fibrillar matrix proteins
[5]. In gliomas, the development of extensive microvascular
proliferations is associated with a large increase in basement
membrane components such as laminin, collagen IV and
fibronectin. In addition, an increased deposition of tenascin-C,
hyaluronan and vitronectin is found associated with the tumors
cells. For the latter two components, this is frequently accompa-
nied by enhanced expression of their respective adhesion
receptors, CD44 and avb3 integrin [6,7]. In contrast, surprisingly
little is known the fibrillar matrix components that are a major
ECM component in other tumor types. For example, it has been
reported that the most abundant of the fibrillar collagens, collagen
I, is absent in GBMs [8,9]. Here we have re-examined the
presence of collagens in gliomas and show using complementary
methods that intratumoral fibrillar collagen can be observed in
nearly a third of the GBM cases. Furthermore, we correlate this
ECM deposition with the expression of the collagen internalization
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9808receptor Endo180 and show that this receptor plays a critical role
in glioma invasion.
Results
Endo180 is highly expressed in GBM
Endo180 is large transmembrane glycoprotein that constitu-
tively recycles between the plasma membrane and intracellular
endosomes [10,11,12]. In normal healthy tissues, expression of
Endo180 is predominantly restricted to cells of mesenchymal
origin, in particular stromal fibroblasts [13,14,15]. Both cell based
and in vivo experiments have demonstrated that Endo180 binds
collagens and functions to internalize them for delivery to,
and degradation in, the lysosomes [16,17,18]. In silico analyses
of independent gene expression datasets in ONCOMINE
TM
[19,20,21,22,23] revealed that Endo180 (MRC2) transcripts were
significantly upregulated in grade IV gliomas, i.e. GBMs, versus
grade III gliomas (Figure 1A). By combining these five studies,
Endo180 was ranked as the 6
th most highly upregulated gene in
GBMs versus grade III gliomas (p=5.56610
25) (Table S2). To
corroborate the in silico analysis, we first examined the expression
and distribution of Endo180 protein by immunohistochemistry in
11 archival high-grade glioma samples for which whole tissue
sections were available. Representative immunohistochemistry
images are shown in Figure 1B. In the 2 grade III anaplastic
astrocytomas, 80–90% of the tumor cells were glial fibrillary acidic
protein (GFAP) positive and 30–40% of the tumor cells showed
low level Endo180 expression. In the 9 GBMs, high level Endo180
expression was detected in 80–100% of tumor cells. The
concentration of perinuclear Endo180 staining is consistent with
the known distribution of this recycling receptor to intracellular
endosomes [11,12]. Endo180 protein was not detected in the
normal brain apart from weak expression in some cells associated
with the vasculature.
Next we examined a series of 79 grade III and IV glioma cases
collected in a tissue microarray (TMA). We observed Endo180
expression in 62/79 (78.5%) samples. In agreement with the in
silico transcript analysis, there was a significantly higher proportion
of Endo180 positive cases in grade IV GBM (59/69, 85.5%)
compared to the grade III lesions anaplastic astrocytoma (1/5,
20%) or anaplastic oligodendroglioma (2/5, 40%) (Table 1, grade
IV versus grade III, p=0.0005, Fishers exact test).
Recently, Phillips and colleagues have described three prog-
nostic subclasses of high-grade glioma: proneural, proliferative and
mesenchymal [24]. Interrogation of their expression profiling data
revealed that Endo180 was strongly correlated with the mesen-
chymal subclass (p,0.005), placing Endo180 positive tumors into
a poor survival cohort characterized by increased neovasculariza-
tion and expression of neural stem cell markers (Figure 2).
TGF-b regulates Endo180 expression in glioma cell lines
Several mechanisms could account for the increased expression
of Endo180 in GBMs. We excluded genetic and epigenetic
regulation as no genomic amplification of the Endo180 locus
(MRC2) at 17q23 was detected in 11 glioma cell lines [25] and the
Endo180 promoter was unmethylated in all cell lines tested, with
the exception of UW479 (Figure S1). Several growth factors
pathways, particularly those downstream of the epidermal growth
factor (EGF), platelet-derived growth factor (PDGF) and TGF-b
receptor families, have been shown to be activated in gliomas
[26,27]. EGF and PDGF-BB treatment of the glioma cell line
U87MG had no effect on Endo180 protein levels however TGF-
b1 treatment resulted in increased Endo180 expression (Figure 3A).
Luciferase reporter assays were performed with human Endo180
promoter fragments to determine the TGF-b responsive region.
TGF-b1 treatment resulted in a 5-fold increase in luciferase
expression from the 21146bp/0bp Endo180 promoter fragment
but only a 1.3-fold increase from the shorter 2649bp/0bp
fragment (Figure 3B). The 21146bp/0bp Endo180 promoter
fragment was then used to determine whether the TGF-b
responsiveness was directly mediated via downstream Smad
signaling. To address this, U87MG cells were treated with Smad3
inhibitor, SIS3 [28]. The type I TGF-b receptor inhibitor,
SB431542, was used as a control for inhibition of total TGF-b
signaling [29]. SIS3 treatment caused a significant decrease in
Endo180 promoter activity in the presence of TGF-b1 (2.3-fold
decrease, p=0.0022) (Figure 3C). This inhibition was similar to
the relative decrease observed with the Smad-responsive control
vector, CAGA12-luciferase (2.0-fold decrease, p=0.0190) [30].
SB431542 treatment completely prevented TGF-b1 induction of
Endo180 promoter activity. Immunoblotting confirmed that
SB431542 treatment completely prevented the phosphorylation
of Smad2 and Smad3, whereas SIS3 treatment was less effective
consistent with its partial prevention of Endo180 induction by
TGF-b1. Interestingly, both inhibitors reduced the baseline level
of Endo180 expression indicating that there is a low-level of
autocrine TGF-b stimulation in U87MG cells.
Collagen uptake in glioma cells is Endo180-dependent
Tumors need to remodel the ECM to physically expand and
liberate latent growth factors [31,32]. A major function of
Endo180 is to internalize collagens for intracellular degradation
[16,17,18]. To test if Endo180 similarly functions as a collagen
internalization receptor in glioma cells, U87MG and SF188 cells
were treated with Endo180 or control siRNA oligonucleotides and
then incubated with OregonGreen (OG)-collagen for 2 h at 37uC.
Flow cytometry analysis demonstrated that Endo180 expression
was reduced 3.0 and 2.6-fold following Endo180 siRNA treatment
in U87MG and SF188, respectively, and that this was matched
with a 2.3 and 2.8-fold decrease in collagen uptake (Figure 4A,B).
TGF-b1 treatment of U87MG and SF188 glioma lines resulted in
a 2.2 and 1.6-fold increase in cell surface expression of Endo180,
respectively, and again this was matched with a similar increase in
collagen uptake, 2.2 and 1.9-fold (Figure 4B).
Collagen I is present in the extracellular matrix of GBM
If the highly upregulated collagen internalization receptor
Endo180 were to play a functional role in GBMs, it would be
anticipated that it would be in intimate contact with a collagen
containing extracellular matrix. However, although the basement
membrane collagen, collagen IV, is found associated with the
extensive microvascular proliferations characteristic of GBMs, it
has been reported that the GBMs have low or undetectable levels
of the major fibrillar collagen, collagen I [8,9]. Hence it was
important to re-examine whether there is indeed a significant
deposition of a fibrillar collagen matrix in GBMs. To address this,
a number of approaches were taken. First, interrogation of the
ONCOMINE
TM microarray data revealed that within the 100
most highly upregulated genes in GBM compared to grade III
tumors were fibrillar collagen genes and genes encoding collagen
processing enzymes (Table S2). Second, collagen 1 is trimeric
protein comprised of two a1 subunits and one a2 subunits
encoded by COL1A1 and COL1A2 genes, respectively. qPCR
analysis of a panel of glioma cell lines with variable Endo180
expression demonstrated substantial expression of both COL1A1
and COL1A2 transcripts in a subset of these cell lines as compared
to the minor levels detected in normal brain (Figure 4C–D). Of
note, COL1A1, COL1A2 and Endo180 (MRC2) expression in GBM
Endo180, Collagen and Gliomas
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are known to produce high levels of collagen 1 and Endo180
protein. Third, the high-grade glioma samples arrayed in the
TMA (Table 1) and available as whole tissue sections (see Figure 1)
were also subjected to Masson’s trichrome staining to visualize
collagen fibers. In all tumor samples, Masson’s trichrome staining
was detected in association with the angiogenic vasculature
resulting from the substantial deposition of basement membrane
collagens, in particular collagen IV (Figure 5A–B). Analysis of the
tumors in the TMA revealed that 21/69 (30.4%) of GBM samples
and 1/10 grade III tumors also showed extensive collagen fibers
present within the tumor mass. Interestingly, this tumor-associated
collagen staining was significantly associated with Endo180
protein immunopositivity (Table 1, p=0.026, Fishers exact test).
Finally, to confirm that the tumor-associated collagen detected by
Masson’s trichrome staining truly represented the deposition of
fibrillar collagens, consecutive formalin-fixed paraffin-embedded
(FFPE) glioma whole tissue sections were subject to Masson’s
trichrome staining and triple immunofluorescent labeling with
antibodies against collagen I, collagen IV, Endo180 and GFAP
(Figure 5B). Collagen I depositions were observed in three separate
areas: intimately associated with high Endo180 expressing, GFAP-
positive tumor cells, in GFAP-negative stromal regions, and, to a
lesser extent, adjacent to vascular proliferations.
Endo180 promotes glioma invasion through a collagen
matrix
Having demonstrated that a significant proportion of GBMs
have fibrillar collagens deposited within the tumor mass, we next
addressed whether Endo180 played a functional role in promoting
the invasive capacity of these tumors. Despite numerous reports
that Endo180 can mediate collagen uptake for lysosomal
degradation in a variety of cell types, the role of this receptor in
promoting migration through a fibrillar collagen matrix has not
been investigated. To address this, we took two complementary
approaches. First, we monitored the invasion of the glioma cells
lines treated with control or Endo180 siRNA oligonucleotides
through non-denatured collagen I coated Transwell filters.
Endo180 siRNA treated cells showed a significant inhibition of
Transwell migration (59.3% inhibition, p=0.0467) (Figure 6A).
Second, cell lines stably infected with lentiviruses containing
control or Endo180 shRNAs were generated. Of note, the shRNA
targeting sequences were distinct from the siRNA oligonucleotide
targeting sequence thus serving as an additional control for the
RNAi studies. Characterization of the shRNA cell lines revealed
that downregulation of Endo180 expression had no impact on cell
proliferation (Figure 6B). Using an assay of invasion into thick
collagen gels, it was demonstrated that control shRNA glioma cells
readily penetrate into the gel. In contrast, Endo180 shRNA cells
showed a drastic impairment in their ability to invade through a
fibrillar collagen I matrix (p=0.0099) (Figure 6C).
Discussion
The current study shows that Endo180 expression is negligible
in the normal brain but highly upregulated in GBMs as revealed
by expression array analysis and immunohistochemical staining of
patient material. Endo180 is a well-characterized collagen
internalization receptor and its extensive expression in GBMs
required us to evaluate the collagen content in these tumors.
Normal brain ECM is largely devoid of collagens, although some
collagen IV can be detected in vascular basement membranes [5].
Masson’s trichrome staining of a large panel of high-grade gliomas
revealed that two types of collagen depositions were present in
GBMs: the basement membrane collagens seen near microvascu-
lar proliferations, consisting mainly of collagen IV, and fibrillar
collagens associated with adjacent stromal regions and present
within the tumor mass. The existence of fibrillar collagen within
the tumor mass is largely unappreciated in the literature as it was
previously reported that the archetypical fibrillar collagen,
collagen I, is absent in gliomas [8,9], with rare exceptions as
described for gliofibromas [33]. In contrast, our study shows that
Table 1. Correlation between expression of Endo180 in
tumour cells, glioma grade and the presence of intratumoral
fibrillar collagen in a high-grade glioma TMA.
Endo180
Negative Positive p
Grade n=79 0.0005
III 7 3
IV 10 59
Intratumoral Fibrillar
Collagen
Negative Positive
Grade n=79 0.268
III 9 1
IV 48 21
Endo180
Negative Positive
Intratumoral Fibrillar
Collagen
n=79 0.026
Negative 20 37
Positive 0 22
79 grade III and IV gliomas arrayed as a TMA were subject to
immunohistochemical staining with the anti-Endo180 mAb 39.10. Intratumoral
fibrillar collagen was detected using the Masson’s trichrome staining method.
Clinical pathological details and scoring of the individual tumors is shown in
Table S2. Shown here are the statistical correlations calculated using Fisher’s
exact test. There was a significantly higher proportion of Endo180 positive cases
in grade IV versus grade III tumors (p=0.0005). There was no significant
difference in the deposition of intratumoral collagen between grade III and
grade IV tumors (p=0.268). There was a significant association between
intratumoral collagen deposition and Endo180 expression (p=0.026).
doi:10.1371/journal.pone.0009808.t001
Figure 1. Endo180 expression is highly upregulated in GBMs. (A) Normalized expression of Endo180 in grade III gliomas (astrocytomas,
oligodendrogliomas and oligoastrocytomas) and grade IV gliomas (GBMs). Box plots were created by ONCOMINE
TM from five independent expression
array studies. p-values were 5.6610
25 (Shai et al.) [22], 1610
26 (Liang et al.) [21], 2.2610
212 (Sun et al.) [23], 5.9610
28 (Bredel et al.) [19] and
2.3610
212 (Freije et al.) [20]. (B) FFPE whole tissue sections of normal brain (2 samples) and grade III (2 samples) or grade IV gliomas (9 samples) were
H&E stained or immunostained for Endo180 (mAb 39.10) and glial fibrillary acidic protein (GFAP). Representative images of the temporal lobe of
normal brain showing weak expression of Endo180 in some cells associated with the vasculature (arrows); a grade III anaplastic astrocytoma (AA)
showing weak Endo180 expression in GFAP-positive tumor cells (arrowheads), two grade IV glioblastomas (GBM) showing strong Endo180 expression
in tumor cells (black and yellow arrowheads). Scale bar, 100 mm.
doi:10.1371/journal.pone.0009808.g001
Endo180, Collagen and Gliomas
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9808in a subset of GBMs, collagen I is an integral part of the ECM as
revealed by collagen I antibody staining. This discrepancy
between reports is most likely related to the detection method
employed. When we repeated these previous studies and used
peroxidase detection for collagen I immunohistochemical staining,
we obtained an uninterpretable high background labeling.
However, employing a recently optimized technique for high
resolution multiple immunofluorescence labeling of FFPE tissue
followed by confocal microscopy imaging [34] allowed us to
reduce the background staining level and clearly visualize the
collagen I deposition at higher magnification (Figure 5B). This
deposition of intratumoral extracellular matrix components has
three possible origins: they could be produced by adjacent stromal
cells, by normal brain cells that are activated by the invading
glioma cells [35] and/or by the tumor cells themselves as part of
their mesenchymal differentiation (see below) [36]. Our studies
demonstrate that tumor cells do indeed contribute to the
production and deposition of collagen I (Figure 4D, Figure 5B).
Importantly, the positive correlation between intratumoral
collagen deposition and Endo180 expression observed in the
high-grade glioma TMA means that Endo180 will be in intimate
contact with is extracellular ligand and can thereby promote
localized matrix remodeling and turnover.
High-grade gliomas (grade III and IV) have been classified into
three subclasses on basis of their expression profiles: pro-neural,
proliferative and mesenchymal [24]. Interrogation of these array
data placed Endo180 firmly into the mesenchymal subclass, which
is mainly associated with grade IV tumors, predicts for poor
disease outcome and is characterized by excessive neovascular-
ization. The association of Endo180 with the mesenchymal
subclass is consistent with previous observations that Endo180
expression in normal tissue is predominantly restricted to cells of
mesenchymal origin [13,14,15]. In tumors, a shift towards a more
mesenchymal phenotype is a common feature of disease
progression for which Endo180 could serve as a surrogate marker.
Consistent with this, the expression of Endo180 in GBMs is
correlated with tumor grade. Moreover, although tumors of
epithelial origin are predominantly Endo180-negative, expression
of Endo180 in 3–6% of invasive breast cancers correlated with a
basal phenotype and shorter disease-free survival [37]. One of the
potential triggers for a shift towards a more mesenchymal
phenotype is TGF-b, a regulatory cytokine playing multiple roles
in cancer [38] and hyperactivation of the downstream signaling
pathway of TGF-b is often observed in poor prognosis gliomas
[39]. Our in silico analysis of expression array data confirmed
high expression of both TGF-b1 and TGF-b2 and its recep-
tor TGF-b-RI in GBMs (Table S2). Interestingly, cell based
studies demonstrated that TGF-b1 stimulation directly enhanced
Endo180 expression in glioma cells (Figure 3), providing an
explanation for the enhanced expression of Endo180 in GBMs.
Cell invasion in vivo requires that there is a balance between the
requirement for a substrate to migrate on (usually composed of
fibrillar matrix proteins) and the requirement for a space to
migrate through. This study demonstrates, for the first time, that
expression of Endo180 on the tumor cells is required for
productive invasion into 3D collagen matrices (Figure 6). This
result has two important implications. First, it provides a potential
mechanism underlying the rapid disease progression displayed by
GBMs compared to lower-grade astrocytic tumors. Second, it
suggests that targeting Endo180 could limit the ECM turnover by
tumor cells and thereby restrict GBM expansion. Together these
data highlight how invading gliomas can balance the requirement
for de novo matrix deposition and matrix remodeling and identifies
a potential target for the treatment of this devastating disease.
Materials and Methods
Patient material
Brain tumor samples were obtained with written informed
consent. The study, including the consent procedure, was
conducted with specific approval from the Local and Multicentre
Ethical Review Committees from the Royal Marsden NHS
Foundation Trust, Sutton, St George’s Hospital Medical School,
London and King’s College Hospital, London. Normal adult brain
Figure 2. Endo180 expression is associated with the ‘mesenchymal’ subclass of high grade glioma. Boxplots for Endo180 (MRC2)
expression values in the three molecular subclasses of high-grade glioma described by expression profiling [24]: mesenchymal (Mes), proneural (PN)
and proliferative (Prolif). The two MRC2 probe sets, 209280_at and 37408_at, that were present in the array are significantly associated with the
mesenchymal group of tumors (Mann-Whitney U test). Box represents upper and lower quartiles, with median designated by a horizontal line.
Whiskers represent the minimum and maximum non-outlier observations, with outliers (open circles) defined as having a value more than 1.5 times
the interquartile range lower than the first quartile, or higher than the third quartile.
doi:10.1371/journal.pone.0009808.g002
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obtained from the UK Multiple Sclerosis Bank, Imperial College
London. 11 cases were available on whole sections with an
additional 79 cases present on a tissue microarray (TMA) with full
clinicopathological data. The age of the patients ranged from 28–
80 years (Table S1). All cases were reviewed by a pathologist (SP)
to corroborate the diagnosis and assess the staining. Normal adult
brain tissue from patients with no history of neurological disease
were obtained from the UK Multiple Sclerosis Bank, Imperial
College London [40].
Antibodies and cells
Anti-Endo180 mAbs A5/158 and 39.10 directed against the
extracellular domain of Endo180 have been previously described
and characterized [11,37]. Other antibodies were as follows:
rabbit anti-glial fibrillary acidic protein (GFAP, Dako), rat anti-
GFAP (Zymed Laboratories), rabbit anti-collagen I (BP8028,
Acris), rabbit anti-collagen IV (AB6586, Acris), mouse anti-
Smad2/3 (BD Biosciences), mAb phospho-Smad2 (Ser465/467,
138D4, Cell Signaling), anti-phospho-Smad3 (Ser423/425)/
Smad1 (Ser463/465) (Cell Signaling), anti-vimentin (Dako),
Figure 3. Expression of Endo180 is regulated by TGF-b signaling. (A) U87MG cells were stimulated for 24 h with 5 ng/ml TGF-b1, 50 ng/ml
EGF or 50 ng/ml PDGF-BB. Endo180 expression (mAb A5/158) and phosphorylation of the SMAD2 protein was monitored by western blotting. (B)
Schematic diagram showing the Endo180 promoter fragments cloned into pGL3-basic. U87MG cells were transfected with Endo180 promoter
constructs or control vectors, pGL3-empty and pGL3-CAGA12-Luc, and treated with or without 5 ng/ml TGF-b1 for 24 h. Bars represent mean values
from three independent experiments 6 SEM. p-values were generated using the student’s t-test. (C) The 21146bp/0bp Endo180 promoter construct
or the pGL3-CAGA12-Luc vector were transfected in U87MG cells. Cells were treated with TGF-b1 in the presence or absence of the inhibitors SIS3 or
SB431542 for 24 h. Graphs show fold induction as compared to the untreated pGL3-CAGA12-Luc control. Error bars represent two independent
experiments performed in triplicate (upper panel). In parallel, activation of TGF-b signaling was monitored by immunoblotting (lower panel). Dotted
line indicates lanes taken from the same gel at the same exposure.
doi:10.1371/journal.pone.0009808.g003
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9808Figure 5. Fibrillar collagens are abundant in the extracellular matrix of GBMs. Staining was performed on GBMs for which whole tissue
sections were available. Representative images are shown. (A) GBMs stained with Masson’s trichrome. Collagen fibers are stained blue/green, nuclei
are black and erythrocytes red. Left hand panel shows extensive collagen deposition in the basement membranes associated with the tumor vessels
(arrowheads). Right hand panel illustrates collagen fibers within the tumor mass (arrows). Scale bar, 100 mm. (B) Four adjacent FFPE sections of a GBM
were stained as follows: Masson’s trichrome to visualize fibrillar collagens (upper left panel), immunolabeled with glial fibrillary acidic protein (GFAP;
green) and counterstained with DAPI (blue) to visualize tumor cells (lower left panel), immunolabeled with collagen IV or collagen I (white) and
Endo180 (red) and counterstained with DAPI (blue) (upper and lower right panels, respectively). Arrowheads indicate large tumor vessels surrounded
by a basement membrane containing mainly collagen IV and some collagen I. Arrow indicates an adjacent stromal region containing dense collagen I
fibers and smaller tumor vessels. Asterisks indicate GFAP-positive, Endo180-positive regions with extensive collagen I deposition. Scale bar, 150 mm.
doi:10.1371/journal.pone.0009808.g005
Figure 4. Collagen internalization and expression by glioma cell lines. (A–B) U87MG and SF188 glioma cells were transfected with control or
Endo180 siRNA oligonucleotides for 24 h and then cultured for a further 72 h with or without 5 ng/ml TGF-b1. Cells were then cultured for 2 h at
37uC in the presence of 20 mg/ml OG-collagen as previously described [16]. Cells were trypsin treated to remove cell surface associated collagen and
the levels of cell surface Endo180 and internalized collagen were monitored by flow cytometry. (A) Dot plots (isotype matched control labeled cells in
the absence of OG-collagen in grey, antibody labeled cells in the presence of OG-collagen in black) show that reduced cell surface expression of
Endo180 is matched by reduced collagen uptake. (B) Table showing the mean fluorescence intensities normalized to cells stained with a control
isotype matched antibody in the absence of OG-collagen. (C–D) Relative expression of Endo180 (MRC2), COL1A1 and COL1A2 in a panel of 17 glioma
cell lines, normal brain and normal human fibroblasts as measured by qPCR. (C) Graph showing relative Endo180 expression related to the highest
expresser, KNS42, which was set at 100. All grade IV gliomas (black bars) express higher levels of Endo180 compared to grade III tumors (grey bars).
Negligible Endo180 expression was detected in normal brain. (D) Relative expression of the two collagen I genes, COL1A1 (grey bars) and COL1A2
(black bars) related to the highest collagen I expresser, U188MG, which was set at 100.
doi:10.1371/journal.pone.0009808.g004
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Alexa488 goat-anti-mouse IgG2A, Alexa555 goat-anti-mouse
IgG1, and Alexa633 goat-anti-rat IgG (Invitrogen), HRP-conju-
gated goat-anti-mouse IgG (Jackson Immunoresearch), HRP-
conjugated goat-anti-rabbit IgG (Santa Cruz) and APC-conjugat-
ed rat anti-mouse IgG1 (BD Biosciences). Human fibroblasts
(HFFF2, human Caucasian fetal foreskin fibroblasts) were
purchased from the European Collection of Cell Cultures
(ECACC). All cell lines were maintained in DMEM with 10%
FBS and 2.4 mM L-glutamine. For growth factor stimulation, cells
were transferred into low serum medium (DMEM with 1% FBS)
for 24 h before treatment for 24 or 72 h with 5 ng/ml
recombinant human TGF-b1 (R&D systems), 50 ng/ml PDGF-
BB (R&D Systems), or 50 ng/ml EGF (Invitrogen) in DMEM with
1% FBS.
Immunostaining, Masson’s trichrome staining and
confocal imaging
For immunohistochemistry, 3 mm FFPE sections were dewaxed
in xylene, rehydrated through a series of graded alcohols to water
and subjected to high-temperature antigen retrieval in 0.01 M
pH 6.0 citrate target retrieval buffer (Dako). Slides were allowed to
cool for 20 min at room temperature and then incubated with
anti-Endo180 mAb 39.10 (20 mg/ml) or 1:1000 anti-GFAP for 1 h
at room temperature. Detection was achieved with the Vectastain
avidin-biotin complex (ABC) system according to the manufac-
turer’s protocol (Vector Laboratories, Burlingame, CA, USA).
Slides were rehydrated through a series of alcohols, cleared in
xylene and mounted in 1,3-diethyl-8-phenylxanthine. Adjacent
sections were stained with haematoxylin and eosin (H&E) or by
the Masson’s trichrome technique to visualize collagen fibers.
Images were captured on a Leica DMRA2 microscope fitted with
a Leica DFC320 camera.
A TMA consisting of 79 WHO grade III and IV gliomas was
stained with the anti-Endo180 mAb 39.10 and the Masson’s
trichrome technique. Endo180 positivity was recorded for cores with
widespread moderate to strong immunoreactivity, with samples
containing only occasional weak staining tumor cells regarded as
negative. Cores were considered positive for intratumoral collagen
deposition where specific blue/green staining was observed within
the tumor mass by the Masson’s trichrome, and distinct from
staining of the vascular basement membrane.
The protocol for the staining of FFPE material for confocal
microscopy is described elsewhere [34,41]. Fluorescent images
were captured on a Leica Microsystems TCS-SP2 confocal.
RNAi
The Endo180 targeting and Endo180 reversed siRNA oligonu-
cleotides, and the protocol for cell transfection has been previously
described [16]. For shRNA downregulation, cells were plated at
1.6610
4 cells per well in a 96-well plate overnight. The following
day, the media was replaced with fresh media containing
hexadimethrine bromide (8 mg/ml) (Sigma) and Mission lentiviral
particles (Sigma) TRCN0000029674 (Endo180 shRNA) or
TRCN0000068276 (control shRNA) added at a multiplicity of
infection (MOI) of 10. Cells were incubated for 12 h before
replacing the media with fresh DMEM plus 10% FBS. 36 h later,
the medium was replaced with DMEM plus 10% FBS and
puromycin (3 mg/ml) and cultured for a further 14 days. Cell
populations were then cultured without puromycin.
Reporter assays
Promoter fragments were generated by PCR with a reverse primer
that started at 21 position of the ATG of Endo180 and four different
forward primers located at different positions in the Endo180
promoter, generating products of 1498bp, 1145bp, 649bp and 390bp
respectively. The sequence for reverse primer hEndo180R-0 bp was
59-AAAAGCTTCCCCGAGCGCGGCGCTCAGT-39 and for the
four forward primers were: hEndo180F-1498bp: 59-AAAGATC-
TAGCATTTCTGACCCAACACC-39, hEndo180F-1146bp: 59-T-
CTCAACGTCTCAGTCCTGC-39, hEndo180F-649bp: 59-GAG-
GTAGGGGATGCTAGGCT-39, hEndo180F-390bp: 59-G G G A -
GAGACTGGGAAACAGA-39. The PCR products were cloned
into the luciferase reporter vector, pGL3-basic (Promega) and verified
by DNA sequencing. The 2140bp/0bp Endo180 promoter frag-
ment was generated by digestion of the pGL3 21498bp/0bp vector
with MscI and SmaI and self-ligating the digested vector. Smad
binding elements in 21146bp/0bp Endo180 promoter fragment
were mutated using the Quickchange II XL kit (Stratagene) and
primers: mutSBE1F 59-GTAACACTGAGTAACTGTGGATTA-
ACTAACCTTTTATGAAATTTC-39,m u t S B E 1 R5 9-GAAAT-
TTCATAAAAGGTTAGTTAATCCACAGTTACTCAGTGTT-
AC-39,m u t S B E 2 F5 9-GAGTGATGATGCCGAACTTCTGGG-
ACGTCCAG-39,m u t S B E 2 R5 9-CTGGACGTCCCAGAAGTTC-
GGCATCATCACTC-39.T h ep G L 3C A G A 12-Luciferase reporter
plasmid has been described previously [30]. The reporter assay was
performed as previously described [42] with the following modifica-
tions. Briefly, U87MG cells were plated at low density. The next day,
cells were transfected with the indicated reporter plasmids using
FuGENE6 transfection reagent (Roche). The day after, cells were
cultured in DMEM containing 1% FBS in the presence or absence of
5n g / m lT G F - b1. After 24 h, cells were harvested in passive lysis
buffer and luciferase activity was determined using the Promega
luciferase assay system. In all transfections, a b-galactosidase ex-
pression plasmid (pDM2LacZ) was included to normalize the
luciferase activities. b-galactosidase activity was determined in
100 mM Na2HPO4/NaH2PO4,1m MM g C l 2, 100 mM 2-mercap-
toethanol and 0.67 mg/ml O-nitrophenyl-galactopyranoside. Where
indicated, cells were treated with the SMAD3 inhibitor, SIS3
(1.5 mM, Merck) [28] or with the TGF-b type I receptor inhibitor,
SB431542 (20 mM, Tocris) [29], simultaneously with the TGF-b1
treatment.
Collagen internalization
Cells were transfected with control or Endo180 siRNA
oligonucleotides for 24 h and then treated with or without 5 ng/
ml TGF-b1 for 72 h. Cells were then incubated with 20 mg/ml
Figure 6. Endo180 mediates invasion of glioblastoma cells through a collagen matrix. (A) SF188 cells were treated with control or
Endo180 siRNA oligonucleotides. After 48 h, cells were plated on Transwell inserts coated with collagen I and allowed to migrate towards a high
serum concentration for 24 h. Data represents .6 independent experiments. Parallel cultures were subject to immunoblotting to confirm siRNA
mediated Endo180 downregulation. (B) Growth of SF188 cells stably infected with control or Endo180 shRNA lentiviruses was monitored over 4 days
using Cell Titre-Glo and subject to immunoblotting to confirm shRNA mediated Endo180 downregulation. Error bars represent mean values from two
independent experiments each with triplicate samples 6SEM. (C) Control and Endo180 shRNA infected SF188 cells were plated onto a thick collagen
I-containing gel and cultured for 11 days. Gels were embedded, sectioned, immunostained with vimentin and an invasion index calculated. Left hand
panel shows representative images. Arrows indicate depth of matrix. Right hand panel shows invasion index from 4 independent experiments each
with duplicate or triplicate samples. p-values were generated using the student’s two-tailed t-test.
doi:10.1371/journal.pone.0009808.g006
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37uC before being harvested using trypsin/EDTA for 5 min at
37uC. Cells were stained on ice with anti-Endo180 mAb A5/158
or mouse IgG1 for 30 min followed by an APC-conjugated rat
anti-mouse IgG1 antibody for 30 min. Cells were washed twice
and FACS analyzed in the presence of propidium iodide.
Invasion assays
For Transwell migration assays, siRNA transfected cells
cultured for 24 h in DMEM with 1% FBS were trypsinized and
5610
4 cells were plated, in the same medium, onto 6.5 mm
Transwell inserts (8.0 mm pores; Costar) that had been pre-coated
with 50 mg/ml collagen I (PureCol, Inamed Biomaterials). The
lower well contained DMEM plus 10% FBS. After 24 h, invaded
cells on the underside of the filter were methanol fixed and stained
with 1% toluidine blue/1% borax solution. The membrane was
excised and three photos were taken of each insert at 106
magnification. Cells were counted using the ImageJ software.
Collagen gel invasion assays were performed as previously [43]
with the following modifications. 5610
5 glioma cells were plated
into 24 well plates containing a 1 ml gel comprising a 1:1 mix of rat
tail collagen type 1 (BD Biosciences; 3.7 mg/ml) and Matrigel (BD
Biosciences; 12.1 mg/ml) and incubated overnight at 37uC. The
following day, the cultures were raised to an air-liquid interface and
fed from the underside every two days with DMEM plus 10% FBS
and 50 ng/ml EGF (Invitrogen) for 11 days. At the end of the assay,
gelswerefixedin4%paraformaldehydebeforebeingformalin-fixed
and embedded in paraffin wax. 3 mm sections were taken from the
centre of each gel and immunostained with anti-vimentin antibody
to detect the glioma cells. Images were analyzed using ImageJ
software to count the number of invaded particles containing $1
cell (N), the total area invaded (A), and the depth of invasion (D).
The invasion index is calculated as N6A6D [43].
Bioinformatic analysis
A profile search for glioblastoma was performed on the
ONCOMINE
TM database [44]. Five expression profiling studies
were selected that compared grade III gliomas (astrocytoma,
oligodendroglioma and oligoastrocytoma) with grade IV gliomas
(GBM) [19,20,21,22,23]. A ranked list of genes differentially
expressed between grade III and IV tumors across all of these
studies was calculated by T statistics. For the expression data from
Phillips and colleagues [24] differential expression between the
classes was calculated for the two MRC2 probe sets using the
Mann-Whitney U test.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0009808.s001 (0.08 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0009808.s002 (0.05 MB
PDF)
Figure S1 Endo180 promoter methylation. Methylation of
Endo180 in intronic region +375bp/+579bp was monitored using
a methylation-sensitive PCR (MSP). Briefly, 1 mg of genomic DNA
from normal brain and 19 glioma cell lines was subjected to sodium
bisulphite conversion using EZ DNA Methylation Kit (Zymo
Research) after which MSP was performed in a reaction volume of
20 ml for 40 cycles. Amplification products were resolved on 1.5%
agarose gels and visualized under UV illumination to compare
unmethylated (U) and methylated (M) amplifications. The following
Endo180 primers were used: MRC2U-F 59-ATTTTAGTAGTT-
TAGGAGGAAGTGG-39. MRC2U-R 59-TAATTAAAAAAC-
CATCCTAACACA-39. MRC2M-F 59-GGATTTTAGTAGTT-
TAGGAGGAAGC-39. MRC2M-R 59-AATAATTAAAAAACC-
GTCCTAACG-39. In 18 out of 19 cell lines and in normal brain no
promoter methylation was detected. Cell line UW479 showed a
methylated promoter status that corresponded with an absence of
Endo180 gene transcript as tested by qPCR (see Figure 4C).
Found at: doi:10.1371/journal.pone.0009808.s003 (0.29 MB TIF)
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